Chinese biotech firm Bao Pharmaceuticals has secured over $100 million in a Series B round of financing led by Oriental Fortune Capital to ramp up its efforts to develop and commercialise recombinant protein drugs and antibody drugs.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
